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Abstract
Objective—To determine the associations between joint metabolism biomarkers and hand
radiographic osteoarthritis (rOA, based on Kellgren Lawrence [KL] grade ≥2), symptoms, and
function.
Design—Cross-sectional data were available for 663 participants (mean age 63 years, 63%
white, 49% women). Three definitions of hand rOA were considered: 1) a composite measure
involving at least 3 hand joints distributed bilaterally with 2 of 3 in the same joint group, including
≥1 distal interphalangeal joint, without metacarpophalangeal [MCP] swelling); 2) rOA in at least
one joint of a group; and 3) number of joints with KL ≥2. We assessed hand symptoms and the 15-
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item AUSCAN (Likert format). We measured serum cartilage oligomeric matrix protein
(sCOMP), hyaluronic acid (sHA),carboxy-terminal propeptide of type II collagen (sCPII), type II
collagen degradation product (C2C), urinary C-terminal crosslinked telopeptide of type II collagen
(uCTX-II), and urinary N-terminal crosslinked telopeptide (uNTX-1). Linear regression models
were performed to assess associations between each biomarker with hand rOA, AUSCAN, and
symptoms, adjusting for age, gender, race, current smoking/drinking status, BMI, and hip and
knee rOA.
Results—In adjusted analyses, MCP (p<0.0001) and carpometacarpal rOA (p=0.003), and a
higher number of hand joints with rOA (p=0.009), were associated with higher levels of sHA.
Positive associations were seen between AUSCAN and hand symptoms and levels of sCOMP
(p≤0.003) and sHA (p≤0.048).
Conclusion—Hand symptoms and higher AUSCAN scores were independently associated with
higher levels of both sCOMP and sHA; hand rOA was associated only with sHA levels.
Keywords
Hand joints; Biomarkers; osteoarthritis; radiography
Introduction
Radiographic osteoarthritis (rOA) of the hand is extremely common, occurring in
approximately half of adults over age 55 years (1, 2). Symptomatic hand OA is less
frequently seen, with estimates in the range of 3–8% of older adults (2, 3). Functional
limitations and disability related to hand OA can be substantial (4–7), even for
“asymptomatic” rOA (8). The multiple possible joints involved and varying patterns of joint
involvement lead to various definitions of what constitutes hand OA, making it difficult to
compare studies and outcomes. Alternate methods of assessing hand OA, such as the
utilization of biomarkers, could provide a quantitative measure of OA and assist in
characterizing clinically relevant aspects of the hand OA pathophysiologic process.
Biomarkers are a promising alternative means of diagnosing and monitoring OA early in the
disease process and may have the potential to predict the development and progression of
OA (9). Several biomarkers have been identified as indicators of OA involvement at
commonly affected large joint sites such as the knee and hip (9–12). Regarding hand OA,
Kraus, et al, examined systemic biomarker levels with total body burden of OA in women
and found that some hand joint groups, particularly CMCs, contributed disproportionately to
specific biomarker measurements (13). Hyaluronic acid, found in cartilage and connective
tissue throughout the body, was elevated in women with erosive hand rOA in comparison to
those with non-erosive forms (14, 15). A marker of cartilage catabolism was elevated in
erosive and nodal OA compared with controls, although no markers were different between
erosive and nodal OA patients (16). Several inflammatory factors (c reactive protein, TNF-
alpha, interleukins, and MCP-1, among others) have also been linked to hand rOA (17–19),
although these findings have not been consistent (15, 20). Using principal components
analysis, the Genetics of Osteoarthritis and Progression (GARP) study has identified
associations between hand OA and several biomarkers including urinary C-terminal
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crosslinked telopeptide of type II collagen (uCTX-II) and serum cartilage oligomeric matrix
protein (COMP) (21). CTX-II may also be useful in monitoring treatment response in hand
OA (22). Many of these studies were small and/or had limited data on OA at other joint
sites, which is highly relevant since OA at other joint sites may contribute to systemically
measured biomarkers in serum and urine.
The aim of this study was to improve understanding of associations between biomarkers and
hand OA, to inform future work on specific aspects of biomarkers in hand OA, such as
diagnostic and prognostic performance characteristics. The present study was designed to
explore associations between 6 systemic biomarkers of joint metabolism reflecting bone,
cartilage, and synovial involvement and several radiographic and clinical manifestations of
hand OA in a relatively large sample of white and African American men and women from
the Johnston County Osteoarthritis Project (JoCo OA).
PARTICIPANTS AND METHODS
Participants in this study were from the JoCo OA, an ongoing community-based study of
OA and its risk factors in North Carolina. As reported previously, this well-characterized
cohort includesnon-institutionalized individuals, aged 45 years and older,from six selected
townships in Johnston County NC (23).The biomarkers sub-study was performed from
2003–2008 on a subset of participants (n=671) selected to represent a balance by gender
(50% female) and to include a large proportion of African Americans (37%) (24).
Participants with radiographic evidence of rheumatoid arthritis were excluded. This analysis
includes data on those participants in the sub-study who had data for at least one biomarker
(n=661), BMI (n=662), the AUSCAN index (n=658), and hand rOA (n=638). The JoCo OA
has been continuously approved by the Institutional Review Boards of the Centers for
Disease Control and Prevention and the University of North Carolina at Chapel Hill.
Demographic and Clinical characteristics
Self-reported gender, race (white or African American), age, current smoking (yes/no), and
current drinking status (yes/no) were collected during home interviews. Height without
shoes was measured in centimeters, and weight was measured in kilograms (kg) with a
balance beam scale during the clinic assessment. BMI was calculated as weight in kg/height
in meters squared. Hand symptoms were assessed by the NHANES I question (25) “On
MOST days, do you have pain, aching, or stiffness in your hands?”
Australian Canadian Hand Osteoarthritis Index (AUSCAN)
AUSCAN is a valid and reliable self-report 15-item questionnaire that assesses hand
symptoms in those with and without hand rOA (26, 27). AUSCAN was administered, using
the Likert format, by trained interviewers in the JoCo OA to evaluate hand pain, stiffness,
and function experienced in the 2 days prior. There are 5 items for pain, 1 for stiffness, and 9
for function, addressing symptoms experienced during various activities such as gripping,
lifting, or turning objects, and about difficulties with activities such as opening new jars or
fastening clothes or jewelry. Each item is scored from 0 (none) to 4 (extreme), yielding a
total possible score of 60, with higher scores indicating worse pain and function.
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Bone and Joint tissue biomarker assays
Blood for serum and second morning void urine samples were obtained and then stored at
−86°C, as previously reported (24).
Urine NTX-I (cross linked N telopeptide of type I collagen): Osteomark NTX Urine kit was
used to measure urine NTX levels. A competitive-inhibition enzyme linked immunosorbent
assay (ELISA) was used withreported precision of 7.6% intra-assay and 4.0% inter-assay
variability (Osteomark Performance data online at http://www.osteomark.com). Final results
were corrected for urine creatinine concentration.
Urine CTX-II (urinary C-telopeptide fragments of type II collagen): this biomarker was
measured with the Urine Cartilaps competitive ELISA. The reported precision was between
4.6–7.8% intra assay and 6.9–12.2% inter assay variability. Final results were corrected for
urine creatinine concentration.
Serum COMP (cartilage oligomeric matrix protein): a sandwich enzyme linked
immunosorbent assay ELISA was used with precision between 5.8–6.6% intra-assay and
8.7–9.7% inter-assay variability (28).
Serum C2C (collagenase-generated cleavage neoepitope of type II collagen): Collagen Type
II Cleavage ELISA (Ibex Pharmaceuticals, Montreal, Quebec, Canada) was used to measure
this biomarker. It has a precision of 9.7% intra-assay (29) and <20% inter-assay variability
(Ibex data sheet).
Serum CPII (type II collagen c-propeptide): the Procollagen II C-Propeptide ELISA (Ibex
Pharmaceuticals, Montreal, Quebec, Canada) was used to measure CPII levels. The
precision was 6.4% intra-assay (29) and <25% inter-assay variability (Ibex data sheet).
Serum HA (hyaluronan): the Hyaluronic Acid Test kit (Corgenix, Westminster, CO), an
enzyme-linked binding protein assay, was used to measure HA levels. The precision was
<5% intra-assay and <7.0% inter-assay variability.
Radiographic Assessment
Bilateral posteroanterior radiography of the hands, and of the knees in fixed flexion (~20
degrees) and weight bearing was conducted for all participants. All men and women over 50
had a supine anteroposterior pelvic radiograph. A single musculoskeletal radiologist (JBR)
read all radiographs with high intra-rater reliability (weighted kappa 0.9) (23). Radiographs
were assessed using the Kellgren Lawrence (KL) radiographic atlas for knee, hip, and hand,
with a KL score of 2 or more used to define rOA (30).
Hand rOA was defined primarily using the GOGO definition (31), as a KL grade ≥ 2
involving at least 3 hand joints (distal and proximal interphalangeal [DIP and PIP], or
carpometacarpal [CMC]) distributed bilaterally with 2 of 3 in the same joint group,
including at least one DIP, and without MCP swelling on physical examination. We also
explored alternative definitions including:joint group, where rHOA was present in at least
one joint (DIP, PIP, metacarpophalangeal [MCP], CMC) of a joint group (e.g. if at least one
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DIP had a KL ≥ 2, the criteria for DIP rOA were met); and the total number of hand joints
affected by rHOA across both hands (0–30).
Statistical Analysis
Descriptive statistics were calculated for the whole sample and also for subgroups of interest
(e.g. GOGO hand rOA). Frequencies and percentages were computed for categorical
variables (gender, race, smoking, drinking, knee rOA, hip rOA, and hand rOA variables) and
the median and total range for continuous variables (age, BMI, AUSCAN and each
biomarker: uNTX-I, uCTX-II, sCOMP, sC2C, sCPII, [C2C:CPII], and sHA). For AUSCAN,
we focused on the total score, as the results were similar for the total score and the
individual pain and function subscales, although these values are also mentioned in the text.
Chi-square statistics for categorical variables and one-way ANOVA testing of linear trend
for continuous variables were used to compare hand OA and non-hand OA groups.
Spearman partial correlation coefficients were examined between the AUSCAN total score
and each biomarker and between the individual biomarkers.
Separate multiple linear regression models were used to examine the associations between
each of the ln-transformed biomarkers and each of the main hand OA variables of interest
(GOGO hand rOA, DIP rOA, PIP rOA, MCP rOA, CMC rOA, number of joints with hand
rOA, AUSCAN total score, and hand symptoms). Natural log-transformation allowed the
distribution of each biomarker to approximate a normal distribution; these transformed
values were used in the models. Based on a priori hypotheses regarding potentially
important confounders, regression models were adjusted for age and BMI as continuous
variables, and categorical race, gender, smoking, drinking, and rOA status in the knee and
hip. We also explored stratification by race for GOGO hand rOA and hand symptoms.
Those models evaluating associations between biomarkers and the AUSCAN were
additionally adjusted for GOGO hand rOA. A Bonferroni correction was applied to the p
values from the final model, adjusting for 8 models (8 different main hand variables) per
biomarker outcome.
Each of the adjusted regression models started with a full model including all two-way
interactions between the main hand OA variable and the adjusting covariates, as well as the
polynomials of the continuous main hand OA variables (number of hand joints and
AUSCAN total score) up to the third power. At this point, backward selection was
conducted to remove one interaction, or the highest order polynomial term, at a time until all
p < 0.1. A p-value < 0.1 for an interaction term was considered noteworthy for potential
effect modification; based on this criterion, no interactions were identified. Due to a large
number of individuals with a “0” value for AUSCAN, we explored categorizing AUSCAN
total into tertiles, quartiles and quintiles with similar results; we report the results using
tertiles (tertile 1=0, tertile 2 range 1–10, and tertile 3 range 11–53) which divided the sample
most evenly.
RESULTS
Demographic and clinical characteristics, overall and by GOGO hand rOA status, are shown
in Table 1. Participants had a medianage of 63 years and BMI of 29 kg/m2. About two-thirds
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of all participants were white and half were women. There were 20% current smokers, and
28% current alcohol drinkers. Knee rOA was present in about one-third of the sample, while
hip rOA and GOGO hand rOA were present in about one quarter. DIP and PIP rOA were
identified in 40% and 32%, respectively, while 11% had MCP rOA and 22% had CMC rOA;
the median number of hand joints affected was 1 (range 0–20). The median total AUSCAN
score was 3, with a range from 0 to 53. Hand symptoms were present in 44% of the sample.
Those participants with hand rOA by the composite GOGO definition were older, more
often white, less likely to be current smokers or alcohol drinkers, more likely to have
concomitant knee or hip rOA, more likely to report hand symptoms, and had a slightly
higher AUSCAN score (Table 1).
The levels of each biomarker overall and by GOGO hand rOA, are also shown in Table 1.
Urinary CTXII and sHA levels were higher in those with hand rOA compared to those
without; levels of the other biomarkers were not statistically significantly different.
AUSCAN total score was positively associated with levels of sCOMP (p=0.006), and there
was a borderline association with sHA (p=0.057, Table 2). Statistically significant crude
associations were also seen between hand symptoms and uNTX-1 and sCOMP, and between
AUSCAN and uNTX-1 and sCOMP (data not shown).
sCOMP
In models adjusted for rOA in the hands, knees, or hips and demographics (Table 3), ln
sCOMP was significantly higher in those participants in the highest tertile of AUSCAN
score (>11) compared to those with an AUSCAN total score of 0 (the lowest tertile), such
that the ln sCOMP level would be 0.13 units higher in an individual with a highest tertile
AUSCAN score compared with an individual in the lowest AUSCAN tertile. Similar results
were observed for AUSCAN pain (beta 0.14, p=0.003) and function (beta 0.10, p=0.025)
subscales, and hand symptoms (beta 0.11, p=0.001). The association between ln sCOMP and
hand symptoms was similar among African American and Caucasian participants in
stratified analyses. After adjustment for rOA in the knees and hips, there were no significant
associations of ln sCOMP and any of the hand rOA variables.
sHA
In models adjusted for rOA in the hands, knees, or hips and demographics (Table 3), ln sHA
was also significantly higher (by 0.18 units) in those participants in the highest tertile of
AUSCAN score compared to those in the lowest tertile. Similar results were observed for
the AUSCAN pain (beta 0.16, p=0.056) and function (beta 0.10, p=0.076) subscales, and
hand symptoms (beta 0.16, p=0.034).Ln sHA was positively associated with presence of
MCP or CMC rOA, such that ln sHA was 0.55 units higher in those with MCP rOA than in
those without, and 0.30 units higher in those with CMC rOA versus those without. Also, for
each additional hand joint with rOA (0–30), there was a small but statistically significant
increase in ln sHA (beta 0.03 [95% CI 0.01–0.05], p value 0.009). There was no association
between sHA and presence of DIP or PIP rOA, or GOGO hand rOA, and results were
similar in analyses stratified by race.
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Associations between ln sCOMP and AUSCAN and hand symptoms, and ln sHA and MCP
rOA and CMC rOA, remained significant after Bonferroni adjustment (Table 3). There were
no other statistically significant associations between hand variables and biomarkers;
specifically, the association between uNTX-I and AUSCAN wasno longer statistically
significant in adjusted models. Additional analyses restricted to a smaller age range (due to
observed age differences in those with and without GOGO rOA) were similar to the full
sample (data not shown). Stratification by race, although limited by smaller sample size,
revealed a borderline association between GOGO rOA and uNTX-I (p=0.08) among African
Americans and between GOGO rOA and uCTX-II in whites (p=0.07).
Discussion
In this analysis of biomarker and hand OA data from a community-based cohort, we found
higher levels of sCOMP and sHA to be associated with higher total AUSCAN scores and
hand symptoms, independent of rOA in the knees and hips. Also independent of other
covariates including age and knee and hip rOA, sHA levels were higher in participants with
MCP or CMC rOA, and for greater numbers of hand joints affected by rOA. Knee rOA
demonstrated statistically significant associations with sHA (as previously shown in this
cohort (10)) and with uCTX-II, but not with other biomarkers, and no associations were seen
between biomarkers and hip rOA in these models including hand variables. Overall, sCOMP
levels primarily reflected hand pain and function rather than structural alterations of OA,
while sHA levels reflected both symptomatic and structural change in hand OA. The present
study, focused on hand OA, supports prior evidence identifying both HA and COMP as
burden of disease biomarkers by the BIPED criteria (32).
The strongest association in this analysis was between MCP rOA and sHA. Several studies
have shown that the MCP joints are commonly affected by rOA (1, 2, 31). More than 36%
of the participants in the Genetics of Generalized Osteoarthritis (GOGO) study had
radiographic MCP involvement (31), similar to a study of participants from Framingham in
which 29–33% had MCP rOA (2). Although only 8% of Rotterdam Study participants had
MCP rOA, it was commonly seen in conjunction with other hand joint involvement (86% of
those with MCP rOA had other hand joint rOA) (1). This high prevalence of OA at MCP
joints is likely underappreciated because the changes on radiographs are not readily apparent
on clinical examination. Associations between joint space narrowing at the MCPs and both
sHA and sCOMP have been reported; sCOMP was also associated with osteophytes at this
joint site (13). The MCP joints may be an early site of hand OA, occurring prior to changes
in other joints as suggested by Kalichman et al (33), potentially making this site more prone
to inflammation and damage associated with HA release.
COMP is found predominately in articular cartilage and is released into the serum as a result
of cartilage turnover (damage and repair)(34). The literature contains many studies that
examine the relationship between sCOMP and knee or hip OA (9, 28, 34); however, there
are few studies that explore this relationship in hand OA. Higher sCOMP levels correlate
with radiographic knee OA progression (28), are higher in those with knee OA versus those
without, and correlate with severity of rOA as well as the number of affected knee and hip
joints (34). Levels of sCOMP are also associated with the presence of hip rOA and
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progression of joint space narrowing at the hip (35). Chen et al. reported sCOMP levels to
be significantly higher in subjects with clinically defined hand OA than in subjects without
hand OA, although this finding was not independent of age (36). Associations have been
found between sCOMP and joint space narrowing at the IP and MCP joints (inversely
associated) and MCP osteophytes (13). Serum COMP, as part of a principal component, was
associated with hand rOA score in the GARP cohort (21). We report an association between
sCOMP and clinical hand symptoms based on the AUSCAN total score and the NHANES-
based interviewer administered question, but not hand rOA alone. This may be due to our
use of composite KL grades rather than individual radiographic features, or may suggest a
“pre-radiographic” stage of OA characterized by elevations in AUSCAN score and hand
symptoms. The small joints of the hands have been shown to contribute to systemic
biomarker levels, so the lack of apparent association is not likely due to the size of the joints
alone (13).
HA is a glycosaminoglycan found in many joint tissues, and is an important component of
articular cartilage and synovium (14). It is a marker for synovitis and joint inflammation and
is influenced by a variety of factors such as food intake, (37) activity levels, and disease
(38). HA has been considered a promising biomarker for OA diagnosis and disease burden
(13, 32, 39). Higher serum levels of HA have been associated with knee KL grades (40),
knee and hip rOA (10, 41, 42), with an increasing number of affected joints (10), higher
total burden of osteophytes (13) and greater number of joint space narrowing faces in the
MCP and CMC joints (13). In the extended CARRIAGE family study, although not
statistically significant, HA was higher among participants with clinically defined hand OA
compared to those without (36). Individuals with erosive hand OA were reported to have
higher systemic levels of HA when compared to those with non-erosive OA; those with
radiographic progression of disease had comparatively higher sHA levels (14). In agreement
with these studies, we found associations between sHA and rOA at the MCPs and CMCs,
independent of OA at other sites. These data suggest that OA in these joints may involve
more synovial inflammation than rOA at other hand joints and/or greater disease severity
than other hand joints confirming that even small joints contribute to systemic biomarker
levels. In addition, we found an independent association between sHA and AUSCAN scores
reflecting hand pain and function. Synovitis by MRI has been associated with hand joint
tenderness and functional indices (although not with AUSCAN) (43) and is accepted to be a
source of pain in knee OA (44, 45). Therefore, elevated sHA in hand OA may be reflective
of early disease with associated hand symptoms.
The many strengths of this analysis include the following: the use of data from a large, well-
characterized cohort comprised of African American and white men and women; the
availability of radiographs for multiple joint sites; the use of multiple biomarkers; and a
relatively large sample size. Limitations of this work include the cross-sectional nature of
the analysis (although future longitudinal studies are possible in this cohort), and the lack of
hand joint-specific symptoms data at this time point. Some of the biomarker assays (for C2C
and CPII in particular), had high variability. We did not have radiographs of additional joint
sites that can be affected by OA such as the shoulders or feet, and our radiographic
assessments were limited to KL grades and did not include individual features of OA such as
osteophytes or joint space narrowing.
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This cross-sectional analysis supports the role of sHA and to a lesser extent sCOMP as
burden of disease biomarkers for hand OA. Independent of rOA at the knee or hip, higher
levels of both markers were associated with hand symptoms and higher total AUSCAN
scores indicating more pain and poorer function, and sHA was also associated with hand
rOA. Longitudinal studies are needed to determine the potential diagnostic or prognostic
potential and performance of these biomarkers in hand OA.
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Table 2
Spearman partial correlation coefficients (adjusted*) between individual biomarkers and AUSCAN Total
Score (n=663).









Adjusted for age, gender, smoking, drinking, knee and hip rOA, and GOGO hand rOA.
uNTX-I: urine cross linked N telopeptide of type I collagen; uCTX-II: urine C-terminal crosslinked telopeptide of type II collagen; sCOMP: serum
cartilage oligomeric matrix protein; sC2C: serum type II collagen degradation product; sCPII: serum carboxy-terminal propeptide of type II
collagen; Ratio: C2C/CPII; sHA: serum hyaluronic acid
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